ACE-031

ACE-031 is a soluble fusion protein combining the extracellular domain of the activin type IIB receptor (ActRIIB) with the Fc portion of human immunoglobulin G1. This creates a 'ligand trap' that circulates in blood and binds myostatin, activins, and GDF11, preventing them from reaching and activating cellular ActRIIB receptors.

The decoy receptor approach provides high-affinity sequestration of multiple muscle-inhibiting ligands, theoretically offering comprehensive pathway inhibition. The Fc fusion extends serum half-life and provides convenient purification through Protein A affinity.

Clinical development focused on Duchenne muscular dystrophy (DMD), where phase 2 studies demonstrated significant increases in lean body mass and bone mineral density. However, development was halted when bleeding events occurred, attributed to effects on BMP9/10 signaling in vascular endothelium - ligands also bound by the ActRIIB trap.

The ACE-031 experience illustrates the challenge of achieving selective myostatin inhibition, as the ActRIIB receptor binds numerous TGF-beta family members with diverse physiological roles. This has driven development of more selective approaches including direct anti-myostatin antibodies and modified decoy receptors with engineered selectivity.